Trial Profile
CHP-753, Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Cyclophosphamide; Methotrexate; Tacrolimus; Thiotepa
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 04 May 2012 Actual patient number changed from 10 to 63 as reported by ClinicalTrials.gov.
- 04 May 2012 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.